By Fineline Cube 
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor Prevymis (letermovir) has received approval from China’s National Medical Products Administration (NMPA). The approval covers both tablet and intravenous formulations for pediatric patients aged 6 months and older weighing ≥6 kg.
Approved Indication
The approved indication includes the prevention of CMV infection and CMV disease in adult patients and children (R+) aged 6 months and above with a body weight of ≥6 kg. The drug is specifically for patients who are CMV seropositive and undergoing allogeneic hematopoietic stem cell transplantation (HSCT).-Fineline Info & Tech